A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
A method for microdissection of the mouse oviduct that allows collection of the individual segments while maintaining RNA integrity is presented. In addition, non-enzymatic oviductal cell dissociation procedure is described. The methods are appropriate for subsequent gene and protein analysis of the functionally different oviductal segments and dissociated oviductal cells.
Mouse model systems are unmatched for the analysis of disease processes because of their genetic manipulability and the low cost of experimental treatments. However, because of their small body size, some structures, such as the oviduct with a diameter of 200-400 μm, have proven to be relatively difficult to study except by immunohistochemistry. Recently, immunohistochemical studies have uncovered more complex differences in oviduct segments than were previously recognized; thus, the oviduct is divided into four functional segments with different ratios of seven distinct epithelial cell types. The different embryological origins and ratios of the epithelial cell types likely make the four functional regions differentially susceptible to disease. For example, precursor lesions to serous intraepithelial carcinomas arise from the infundibulum in mouse models and from the corresponding fimbrial region in the human fallopian tube. The protocol described here details a method for microdissection to subdivide the oviduct in such a way to yield a sufficient amount and purity of RNA necessary for downstream analysis such as reverse transcription-quantitative PCR (RT-qPCR) and RNA sequencing (RNAseq). Also described is a mostly non-enzymatic tissue dissociation method appropriate for flow cytometry or single cell RNAseq analysis of fully differentiated oviductal cells. The methods described will facilitate further research utilizing the murine oviduct in the field of reproduction, fertility, cancer, and immunology.
The murine oviduct is similar in function and morphology to the human fallopian tube1. Both consist of a pseudostratified ciliated epithelium, consisting of two historically described epithelial resident cells: ciliated cells and secretory cells1,2. The oviduct has three classically recognized segments: the infundibulum, the ampulla, and the isthmus. In a recent study, Harwalkar et al.3 investigated oviduct morphology and gene expression leading to the expansion of the categorization of resident epithelial cells to seven distinct populations. In addition, they established the ampullary-isthmus junction as a distinct segment of the oviduct3. The method described herein, which focuses on the infundibulum, ampulla, and isthmus, could easily be extended to include the ampullary-isthmic junction as well2,3. The infundibular region contains the ostium, or opening of the oviduct, and includes the fimbrial region as well as the proximal stalk. Moving toward the uterus, next is the ampulla, and then the isthmus. Ciliated cells are most prominent in the distal end of the region, proximal to the ovary, or infundibulum, while secretory cells are most prominent in the proximal end or isthmus segment1. Unlike the human fallopian tube, the murine oviduct is a coiled structure supported by the mesosalpinx, an extension of the broad ligament peritoneum1,4. In addition, the mouse oviduct is encased in a bursal sac that increases the likelihood of oocyte transfer into the oviduct4. The ampulla is identified as the location of fertilization, from which developing embryos pass into the isthmus before entering the uterus5. Tubal segments are 200-400 μm in diameter and the longer ampullary and isthmus regions are approximately 0.5-1.0 cm in length4. The oviduct distends during the estrous cycle and the ampulla and infundibulum are more distensible than the isthmus1.
Over proliferation of cells, especially secretory cells, characterize precursor lesions to serous tumors found in the pelvic cavity6. These precursor serous intraepithelial lesions arise in the oviduct epithelium solely in the fimbrial region; it is unknown why lesion formation is restricted to this region where normally the predominant cell type is ciliated, not secretory2,7,8. The regionality in terms of normal physiological function, as well as heightened interest in the oviductal origin of ovarian cancer9,10,11,12,13, underscores the importance of separate evaluation of the oviduct segments.
The method described here details the collection of separate oviductal segments for subsequent downstream analyses of segment-specific gene expression and function of dissociated cells. Traditionally, many tissues are processed for whole RNA extraction following either the phenol: chloroform method or an on-column complete extraction method; however, we found that RNA quality was maintained while producing sufficient yield with the described combination method. Utilizing this method, very small functional segments of the oviduct can be processed for downstream analyses rather than investigating the oviduct as a whole, which can mask results representative of the different segments14.
Dissociated murine oviductal cells have rarely been investigated by flow cytometry, most likely due to the limiting cell yield from this tissue. One approach to overcome this problem has been to dissociate cells, grow them in culture, and then stimulate re-differentiation in vitro to obtain appropriate cell numbers for downstream cell analysis15,16,17,18. A limitation to this approach is the time ex vivo and altered microenvironment in culture, both of which likely change gene expression. There is also an assumption that morphological re-differentiation has the same transcriptional and proteomic signature as was present in the intact animal. The current dissociation method was designed to achieve the highest number of epithelial cells in a heterogenous oviductal cell population while maintaining single cell differentiation. Further, the mostly non-enzymatic approach likely limits the loss of cell surface proteins.
All animal handling and procedures were approved by the University of California, Riverside institutional animal care and use committee and were in accordance with guidelines from the American Association for Laboratory Animal Care, the United States Department of Agriculture, and the National Institutes of Health. The described method utilized C57BL/6 adult, female mice. All animals were euthanized by decapitation prior to tissue harvesting.
NOTE: An overview of the protocol, which uses a blue dye to assist in efficient dissection and uncoiling of the oviduct, is shown in the first figure (Figure 1).
Figure 1: Overview of the microdissection method. (A) Left panel shows the intact structure from which most of the ovarian fat pad and remnants of connective tissue surrounding the oviduct have been removed. After this, the addition of toluidine blue helps distinguish the coils of the oviduct (middle panel). Right panel shows structures after the removal of the ovary. (B) An uncoiled oviduct with internal turns for determining where each segment begins and ends. (C) Cartoon of the segmentation used (not drawn to scale). Please click here to view a larger version of this figure.
1. Preparation of the dissection surface
2. Macrodissection of the ovary, oviduct, and uterus
Figure 2: Macrodissection of the ovary and the dissection setup. The oviduct is located dorsally in the pelvic cavity at the base of the kidney within the ovarian fat pad (B). Locate the uterine bifurcation in the pelvic cavity (C) and follow the lateral uterine horn to locate the uterus-oviduct-ovary continuum (B). Remove these structures by cutting through one uterine horn and coarse dissection. Place onto the dissecting platform (A) and affix the uterine portion to dental wax with a needle (A and D). Please click here to view a larger version of this figure.
NOTE: Leave enough uterine horn intact and attached to the oviduct to allow affixation to the dissection platform (Figure 2D).
Figure 3: Step by step oviduct microdissection. Following removal of remnant fat and connective tissue (A,B), add toluidine blue to the tissue (C), and then wash away to facilitate visualization and subsequent removal of the ovary and uncoiling of the tube (D-H). The infundibulum can be found beside the proximal isthmus and uterine-tubal junction (UTJ). Lightly pull the distal end while cutting at the mesosalpinx to uncoil and reveal the endogenous turns of the oviduct (H) to orient for appropriate segmentation. Figure A-C scale bar = 500 μm, D-H scale bar = 400 μm (I) Cartoon of the various segments (not drawn to scale). Please click here to view a larger version of this figure.
3. Microdissection and segmentation of the oviduct
4. Oviduct dissociation
Figure 4: Oviduct cell dissociation, part 1. Cartoon showing how to expose the distal epithelium for optimal cell dissociation (A) and an image showing the easiest way to use the 1 mm2 mesh (B). Please click here to view a larger version of this figure.
5. RNA extraction of oviductal segments
The described dissociation protocol yields 100,000-120,000 cells per mouse with pooling of both oviducts. The method is gentle enough to leave multi-ciliated cell borders intact, allowing for a distinction between multi-ciliated cells and secretory cells, and verifying that the digestion method is gentle enough to prevent de-differentiation. Representative immunofluorescence images in Figure 5 show small cell clumps following step 4.2.1, fixed for 3 min in 4% paraformaldehyde (PFA)/ DPBS, wa...
The three segments of the oviduct are histologically, morphologically, and functionally distinct1,2,3. The epithelium varies greatly from one end of the oviduct to the other. Ciliated cells dominate at the fimbrial/infundibular end, while secretory cells dominate in the isthmic region1. While this overall gradient has been recognized for some time, recent work has uncovered more distinctions among the ovi...
The authors have nothing to disclose.
This work was supported in part by a DoD Breakthrough Award to AMW (BCRP W81XWH-14-1-0425). KCR was partially supported by intramural fellowships: the Pease Cancer Pre-Doctoral Fellowship and the Mary Galvin Burden Pre-Doctoral Fellowship in Biomedical Sciences and University of California, Riverside, intramural awards: the Graduate Council Fellowship Committee Dissertation Research Grant and the Graduate Division Dissertation Year Program Award. The authors thank Gillian M. Wright and Alyssa M. Kumari for assistance in early troubleshooting of this method.
Name | Company | Catalog Number | Comments |
0.5 mm Stainless steel bead mix | Next Advance | SSB05 | Mix 1:1 with 1.4 mm SSB14B, sterilized |
1.4 mm Stainless steel bead mix | Next Advance | SSB14B | Mix 1:1 with 0.5 mm SSB05, sterilized |
1X Dulbecco's Phosphate Buffered Saline A, pH 7.4 (DPBS) | Gibco | 21600-010 | Cold, sterile |
25G needle | BD | 305122 | |
60 mm sterile petri dishes | Corning | 430166 | |
70 μm cell meshes | Fisherbrand | 22-636-548 | |
Agilent Eukaryote Total RNA 6000 Pico Chip kit | Agilent 2100 Bioanalyzer | 5067-1513 | |
Bead Bullet Blender Tissue Homogenizer | Next Advance | BBY24M | |
Bioanlyzer | Agilent 2100 Bioanalyzer | ||
Bovine serum albumin | Sigma Aldrich | A7906 | |
Cold plate/pack/surface of choice | N/A | N/A | Kept at -20C for dissection |
Dental wax | Polysciences Inc. | 403 | |
Dulbecco’s Modified Eagle’s Medium (DMEM)/ Ham’s F12 | Corning | 10-090-CV | Prepare dissection medium: DMEM/ Ham’s F12, 10% FBS, 25 mM Hepes, 1% Pen-Strep |
Fetal Bovine Serum | Corning | 35-015CV | |
Fine point forceps of choice | N/A | N/A | |
Glycine | Sigma Aldrich | G712b | Immunocytochemical validation images |
Goat anti-mouse IgG Alexa Fluor 555 | Invitrogen | A-21422 | Immunocytochemical validation images |
Goat anti-rabbit IgG Alexa Fluor 488 | Invitrogen | A-11001 | Immunocytochemical validation images |
Hepes | Sigma Aldrich | H-3784 | |
Hoescht 33342 | Cell Signaling Technologies | 4082S | Immunocytochemical validation images |
Inverted compound microscope | Keyence BZ-X700 | ||
Mouse anti-mouse Occludin | Invitrogen | 33-1500 | Immunocytochemical validation images |
Non-enzymatic dissociation buffer | N/A | 5 mM EDTA, 1 g/L glucose, 0.4% BSA, 1X DPBS | |
Nylon macro-mesh 1 mm x 1 mm | Thomas Scientific | 1210U04 | |
Paraformaldehyde | Sigma Aldrich | P-6148 | Immunocytochemical validation images |
Pen-Strep | MP Biomedicals | 10220-718 | |
Prolong Gold Antifade Reagent | Cell Signaling Technologies | 9071S | Immunocytochemical validation images: antifade mounting medium |
Pronase | Sigma Aldrich | 10165921001 | Prepare pronase digestion medium: 0.15% Pronase in DMEM/Ham's F12, sterile |
Propidium Iodide | Roche | 11 348 639 001 | Viability validation images |
Rabbit anti-mouse Acetylated-Tubulin | Abcam | ab179484 | Immunocytochemical validation images |
RBC lysis buffer | BD Biosciences | 555899 | |
RNeasy Mini Kit | Qiagen | 74134 | Utilized for on-column purification in text. |
Spring form microdissection scissors | Roboz Surgical | RS-5610 | |
Sterile 3 mL bulb pipettors | Globe Scientific | 137135 | |
Toluidine blue | Alfa Aesar | J66015 | Prepare toluidine blue solution: 1% in 1X DPBS, sterile |
Tris-Buffered Saline-Tween (TBST) | N/A | N/A | Immunocytochemical validation images; 0.1 N NaCl, 10 mM Tris-Cl pH 7.5, 1% Tween 20 |
Triton-X-100 | Mallinckrodt Inc. | 3555 | Immunocytochemical validation images |
Trizol RNA Extraction Reagent | Invitrogen | 15596026 | Referred to as RNA extraction reagent. Nucelase-free water, chloroform and isoproponal are required in supplement of performing Trizol extraction per manufacturer's guidelines |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved